Equity Research Healthcare Plans

Should You Buy Centene Corporation Stock in 2026?

By CirclFi Research Team · · 12/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Centene Corporation (CNC) scores a robust 8.0/10 on our 32-signal Quality of Company framework. At the current market price of $66.43 and a $32.8B market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.

The short answer: 8 of 12 CirclFi valuation models project upside for Centene Corporation (CNC) at $66.42 — the model consensus leans bullish, with a Quality Score of 8.0/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 8 of 12 models see upside — majority bullish
  • Quality Score: 8.0/10 — Strong — above-average quality
  • Value Trap Risk: 17/100 — Minimal — healthy fundamentals
  • Fair Value Range: $7.21 – $292.01 (3950% spread)

Bullish Models

8 / 12

Bearish Models

4 / 12

Quality Score

8.0 /10

Strong — above-average quality

Value Trap Risk

17 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

12 /13
Active Models

Avg. confidence: 37%

Investment Thesis

The Bull Case

Target: $292.01 (+339.6% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Centene Corporation's quality score of 8.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $66.43 and the composite fair value of $115.46 implies +73.8% upside potential.
  • According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model targets a fair value of $292.01 (+339.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Centene Corporation's revenue and margin trajectory in the Healthcare Plans space.

The Bear Case

Target: $7.21 (-89.1%)

  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $7.21 (-89.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +428.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: regulatory rejection risk represents a meaningful risk for Centene Corporation and its Healthcare Plans peers.

Peer Benchmarking

ELV Elevance Health, Inc
9.0
MOH Molina Healthcare In
8.8
PGNY Progyny, Inc.
8.5
HUM Humana Inc.
8.4
CI The Cigna Group
8.3

Valuation Divergence

Spread

3950%

Fair Value Range

$7.21 – $292.01

A 3950% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Sentiment SOTP

$292.01 (+339.6%)

Most Bearish

ML-RIV

$7.21 (-89.1%)

Key Risk Factors

Model Disagreement

3950% spread signals high variance in projections.

Macro/Sector Risk

Healthcare Plans headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View CNC Data Page →

The Bottom Line

Centene Corporation leans positive in our analysis — 8/12 models bullish, composite fair value of $115.46 vs. $66.43, QOC 8.0/10. The case is constructive but not overwhelming, and the 3 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.

These are quantitative model outputs, not investment recommendations. Centene Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy CNC stock right now?

Based on CirclFi's multi-model analysis, 8 of 12 models see upside for CNC at $66.42. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Centene Corporation?

Key risks include: wide model disagreement (3950% spread), signaling high uncertainty; general market and sector-specific risks affecting Healthcare Plans companies. Always diversify and consult a financial advisor.

How does CNC compare to its competitors?

Among Healthcare Plans peers, CNC holds a Quality Score of 8.0/10. Comparable companies include ELV (QOC 9.0), MOH (QOC 8.8), PGNY (QOC 8.5). The relative ranking helps investors identify whether CNC offers better fundamental quality than alternatives in the same sector.

Is CNC a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CNC's Quality Score of 8.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy CNC at?

CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $7.21 to $292.01. At $66.42, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for CNC.

View CNC Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →